Company profile
Imunon, Inc.
NASDAQ:IMNNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Carboplatin | approved | — | 21 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT00441376 | phase1 | completed | 2007-02-01 | 2008-10-01 | Imunon | A Study of ThermoDox™ in Combination With Radiofrequency Ablation (RFA) in Primary and Metastatic Tumors of the Liver |
| NCT00036985 | phase2 | unknown | 2001-08-01 | — | Imunon | Combination Chemotherapy With or Without Microwave Thermotherapy Before Surgery in Treating Women With Locally Advanced Breast Cancer |
| NCT02850419 | phase2 | withdrawn | 2017-03-01 | 2019-12-01 | Imunon | Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients |
| NCT00061867 | phase1 | completed | 2003-03-01 | — | Imunon | Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer |
| NCT01640847 | phase2 | withdrawn | 2012-07-01 | 2013-06-01 | Imunon | MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases |
FDA applications (0)
No records yet.